Study analysis · Annals of the rheumatic diseases · 2025
This weight-loss drug lowers gout-causing uric acid as well as a prescription pill—without the side effects.
Losing weight with tirzepatide drops uric acid in your blood almost as much as taking a gout medicine, and most of that drop is because you lost weight, not because the drug works directly.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study shows that when people took a weight-loss drug, their uric acid levels went down—and most of that drop happened because they lost weight. But it didn’t test if this actually stops gout attacks, so we can’t say for sure it prevents gout.
What’s the bottom line?
This study looked at a drug that helps people lose weight and found it also lowers a chemical in the blood called uric acid, which can cause gout.
How strong is this study?
This study is pretty strong because it came from a real experiment where people were randomly assigned to get the drug or a placebo, and nobody knew who got what. But since they looked at uric acid after the main study was done, we have to be a little careful—like checking the leftovers after dinner instead of planning the meal.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
75 / 100
- Randomizationnot randomized
- Blinding+15/15
- Control group+15/15
- Sample size (n=2539)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design can establish causation. Although this is a post hoc analysis of an RCT, the original trial was randomized and controlled, allowing causal inference for the primary outcome (weight loss). The association between tirzepatide and uric acid reduction is supported by the randomized design, but the mediation analysis (weight loss explaining 72.7% of SUA reduction) is observational within the trial and subject to residual confounding.
Critical COI
Critical conflicts — study credibility is severely compromised
The study was fully funded and controlled by Eli Lilly and Company, whose product (tirzepatide) was being tested, with company employees involved in study design, data analysis, and report writing, raising severe bias concerns.
Funders
Conflict Details
Eli Lilly and Company: Employed by Eli Lilly and Company
Eli Lilly and Company: Employed by Eli Lilly and Company
Eli Lilly and Company: Employed by Eli Lilly and Company
Eli Lilly and Company: Study funded by Eli Lilly and Company
The study is a post hoc analysis of a trial fully funded and conducted by Eli Lilly and Company. Authors employed by the company were directly involved in all key stages of the study, including data analysis and report writing, with no mention of independent oversight or safeguards. This raises significant concerns about bias and the study's independence.
Key takeaways
- 01
People who took the highest dose lost weight and saw their uric acid drop by almost 1 mg/dL — about 5 times more than those on placebo.
- 02
This drop is similar to what low-dose gout medication achieves, meaning weight loss from this drug could help prevent gout flares.
Surprising findings
- Tirzepatide lowered uric acid just as effectively in people with normal baseline SUA as in those with high levels.Most gout treatments target only high-risk patients, but this study shows even those with 'normal' uric acid (under 6 mg/dL) saw significant drops—suggesting prevention, not just treatment, is possible.
- The drug’s effect on uric acid was consistent across all BMI categories—even in those with BMI <30.Since the study focused on obesity, experts expected stronger effects in higher BMI groups. But the data showed no interaction—meaning even 'overweight' (BMI 27–29.9) people benefited.
Practical takeaways
If you’re overweight and have high uric acid or gout, ask your doctor if tirzepatide (or similar GLP-1 drugs) could help you lose weight and lower your gout risk simultaneously.
Tirzepatide is expensive, requires a prescription, and isn’t FDA-approved for gout. It’s also not suitable for everyone—especially those without obesity or with certain medical conditions.
medium confidenceIf you’re on allopurinol and struggling with weight, consider whether weight loss could reduce your medication dose—or even eliminate the need for it.
Never stop or change gout medication without medical supervision. Uric acid rebound after stopping tirzepatide may occur if weight is regained.
medium confidenceWhy this study matters
Weight Loss = Uric Acid Drop
Tirzepatide reduced serum uric acid (SUA) by 0.69–0.95 mg/dL over 72 weeks—nearly 5 times more than placebo (-0.18 mg/dL). Mediation analysis showed weight loss explained 72.7% of this reduction, meaning the drug’s main effect on uric acid comes from shedding pounds, not a direct chemical action.
People think gout meds like allopurinol are the only way to lower uric acid—but this shows that losing weight with a popular obesity drug can do the same job, offering a dual benefit: slimmer waistline and fewer gout flares.
Works Even If You’re Not ‘High Risk’
The uric acid-lowering effect was consistent across all baseline BMI levels (from 30 to over 40) and all baseline uric acid quartiles—even in people with normal or only mildly elevated SUA. P-values for subgroup interactions were non-significant (P=.362 for BMI, P=.610 for SUA).
You don’t need to have gout or super-high uric acid to benefit. Even if you’re just overweight and want to prevent future health issues, this drug could be quietly protecting you from gout down the line.
Equal Effect in Men and Women
Despite gout being 3.26 times more common in men, tirzepatide lowered uric acid equally in both sexes. The study found no significant difference in SUA reduction by sex (Figure 5), challenging the assumption that men are the only ones who need uric acid control.
Women are often overlooked in gout discussions—even though obesity-driven hyperuricemia affects them just as much. This finding flips the script: weight loss meds may be just as vital for women’s joint health.
Comparable to Gout Medication
The SUA reduction from tirzepatide (up to -0.95 mg/dL) is similar to the effect of low-dose allopurinol (0.6–1.0 mg/dL reduction), according to the authors’ comparison to prior studies. This suggests weight loss via tirzepatide could serve as a non-pharmaceutical alternative for uric acid management.
Imagine avoiding daily pills for gout by just using a weight-loss drug that also happens to prevent flares. This blurs the line between obesity treatment and rheumatology care.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at a drug that helps people lose weight and found it also lowers a chemical in the blood called uric acid, which can cause gout.
Research results
People who took the highest dose lost weight and saw their uric acid drop by almost 1 mg/dL — about 5 times more than those on placebo.
What this means - more context
This drop is similar to what low-dose gout medication achieves, meaning weight loss from this drug could help prevent gout flares.
This study tests whether tirzepatide-induced weight loss reduces serum uric acid (SUA) levels in adults with obesity or overweight.
Tirzepatide (5, 10, or 15 mg weekly) significantly reduced SUA by 0.69–0.95 mg/dL over 72 weeks compared to placebo (-0.18 mg/dL), with weight loss explaining 72.7% of the reduction. Effects were consistent across baseline BMI, SUA levels, and sex.
Methods Used
Post hoc analysis of the SURMOUNT-1 trial: 2539 adults with obesity/overweight (BMI ≥30 or ≥27 with comorbidity) randomized to tirzepatide (5, 10, 15 mg) or placebo for 72 weeks. SUA measured serially; mediation analysis quantified weight loss as mediator of SUA reduction.
Main Finding
Tirzepatide reduced SUA by 0.69–0.95 mg/dL (vs. -0.18 mg/dL with placebo) at 72 weeks, with weight loss mediating 72.7% of this effect, independent of baseline BMI or SUA levels.
Confidence Level
High — large, randomized, placebo-controlled trial with robust statistical methods (MMRM, mediation analysis), though post hoc nature limits causal inference for SUA as primary endpoint.
Study Flags
Red Flags
- •Post hoc analysis — not originally designed to test SUA as primary outcome
- •Study population skewed female (67.5%) and White (70.6%), limiting generalizability
- •Gout incidence too low to assess clinical impact on flares
Surprising Findings
Tirzepatide lowered uric acid just as effectively in people with normal baseline SUA as in those with high levels.
Most gout treatments target only high-risk patients, but this study shows even those with 'normal' uric acid (under 6 mg/dL) saw significant drops—suggesting prevention, not just treatment, is possible.
Practical Takeaways
If you’re overweight and have high uric acid or gout, ask your doctor if tirzepatide (or similar GLP-1 drugs) could help you lose weight and lower your gout risk simultaneously.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
High probability
on the GRADE evidence scale
This study shows that when people took a weight-loss drug, their uric acid levels went down—and most of that drop happened because they lost weight. But it didn’t test if this actually stops gout attacks, so we can’t say for sure it prevents gout.
Critical conflicts — the funder had full control over study design, data, and analysis. Study credibility is severely compromised. Score capped at 30.
Strengths
- Large sample size (n=2539)
- Randomized, double-blind, placebo-controlled design (original trial)
- Long follow-up (72 weeks)
Weaknesses
- Post hoc analysis—not pre-specified in original trial protocol
- No adjustment for multiple comparisons in secondary outcomes
- Potential for selection bias in subgroup analyses
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at a drug that helps people lose weight and found it also lowers a chemical in the blood called uric acid, which can cause gout.
Research results
People who took the highest dose lost weight and saw their uric acid drop by almost 1 mg/dL — about 5 times more than those on placebo.
What this means - more context
This drop is similar to what low-dose gout medication achieves, meaning weight loss from this drug could help prevent gout flares.
This study tests whether tirzepatide-induced weight loss reduces serum uric acid (SUA) levels in adults with obesity or overweight.
Tirzepatide (5, 10, or 15 mg weekly) significantly reduced SUA by 0.69–0.95 mg/dL over 72 weeks compared to placebo (-0.18 mg/dL), with weight loss explaining 72.7% of the reduction. Effects were consistent across baseline BMI, SUA levels, and sex.
Methods Used
Post hoc analysis of the SURMOUNT-1 trial: 2539 adults with obesity/overweight (BMI ≥30 or ≥27 with comorbidity) randomized to tirzepatide (5, 10, 15 mg) or placebo for 72 weeks. SUA measured serially; mediation analysis quantified weight loss as mediator of SUA reduction.
Main Finding
Tirzepatide reduced SUA by 0.69–0.95 mg/dL (vs. -0.18 mg/dL with placebo) at 72 weeks, with weight loss mediating 72.7% of this effect, independent of baseline BMI or SUA levels.
Confidence Level
High — large, randomized, placebo-controlled trial with robust statistical methods (MMRM, mediation analysis), though post hoc nature limits causal inference for SUA as primary endpoint.
Study Flags
Red Flags
- •Post hoc analysis — not originally designed to test SUA as primary outcome
- •Study population skewed female (67.5%) and White (70.6%), limiting generalizability
- •Gout incidence too low to assess clinical impact on flares
Surprising Findings
Tirzepatide lowered uric acid just as effectively in people with normal baseline SUA as in those with high levels.
Most gout treatments target only high-risk patients, but this study shows even those with 'normal' uric acid (under 6 mg/dL) saw significant drops—suggesting prevention, not just treatment, is possible.
Practical Takeaways
If you’re overweight and have high uric acid or gout, ask your doctor if tirzepatide (or similar GLP-1 drugs) could help you lose weight and lower your gout risk simultaneously.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
High probability
on the GRADE evidence scale
This study shows that when people took a weight-loss drug, their uric acid levels went down—and most of that drop happened because they lost weight. But it didn’t test if this actually stops gout attacks, so we can’t say for sure it prevents gout.
Critical conflicts — the funder had full control over study design, data, and analysis. Study credibility is severely compromised. Score capped at 30.
Strengths
- Large sample size (n=2539)
- Randomized, double-blind, placebo-controlled design (original trial)
- Long follow-up (72 weeks)
Weaknesses
- Post hoc analysis—not pre-specified in original trial protocol
- No adjustment for multiple comparisons in secondary outcomes
- Potential for selection bias in subgroup analyses
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is pretty strong because it came from a real experiment where people were randomly assigned to get the drug or a placebo, and nobody knew who got what. But since they looked at uric acid after the main study was done, we have to be a little careful—like checking the leftovers after dinner instead of planning the meal.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
75 / 100
- Randomizationnot randomized
- Blinding+15/15
- Control group+15/15
- Sample size (n=2539)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design can establish causation. Although this is a post hoc analysis of an RCT, the original trial was randomized and controlled, allowing causal inference for the primary outcome (weight loss). The association between tirzepatide and uric acid reduction is supported by the randomized design, but the mediation analysis (weight loss explaining 72.7% of SUA reduction) is observational within the trial and subject to residual confounding.
Critical COI
Critical conflicts — study credibility is severely compromised
The study was fully funded and controlled by Eli Lilly and Company, whose product (tirzepatide) was being tested, with company employees involved in study design, data analysis, and report writing, raising severe bias concerns.
Funders
Conflict Details
Eli Lilly and Company: Employed by Eli Lilly and Company
Eli Lilly and Company: Employed by Eli Lilly and Company
Eli Lilly and Company: Employed by Eli Lilly and Company
Eli Lilly and Company: Study funded by Eli Lilly and Company
The study is a post hoc analysis of a trial fully funded and conducted by Eli Lilly and Company. Authors employed by the company were directly involved in all key stages of the study, including data analysis and report writing, with no mention of independent oversight or safeguards. This raises significant concerns about bias and the study's independence.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
5 researchersIf this is your work, this is how we attribute it on Fit Body Science. Naveed A. Sattar is listed as the lead author.